Buy and Sell Signals, and Other Market Perspectives Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Buy and Sell Signals, and Other Market Perspectives

SPY 670.92

+0.1%

Nov 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: GROUND ZERO™ who wrote (152745)	1/22/2021 10:09:59 PM
From: Hawkmoon	5 Recommendations Recommended By Curbstone GROUND ZERO™ Hugh Bett the longhorn Thomas M. Read Replies (1) of 218591

GZ, I think I need to post this and prepare folks for what appears to be some VERY disturbing data that was just released. Some Italian Virologists just pre-print published the results of their experiments in assessing how SARS-CoV-2 mutates in the presence of polyclonal antibodies (convalescent plasma/Vaccines).. This is the abstract from their paper: "To investigate the evolution of SARS-CoV-2 in the immune population, we co-incubated authentic virus with a highly neutralizing plasma from a COVID-19 convalescent patient. The plasma fully neutralized the virus for 7 passages, but after 45 days, the deletion of F140 in the spike N-terminal domain (NTD) N3 loop led to partial breakthrough. At day 73, an E484K substitution in the receptor-binding domain (RBD) occurred, followed at day 80 by an insertion in the NTD N5 loop containing a new glycan sequon, which generated a variant completely resistant to plasma neutralization. Computational modeling predicts that the deletion and insertion in loops N3 and N5 prevent binding of neutralizing antibodies. The recent emergence in the United Kingdom and South Africa of natural variants with similar changes suggests that SARS-CoV-2 has the potential to escape an effective immune response and that vaccines and antibodies able to control emerging variants should be developed. One Sentence Summary Three mutations allowed SARS-CoV-2 to evade the polyclonal antibody response of a highly neutralizing COVID-19 convalescent plasma." biorxiv.org Twitter thread rollout discussion threadreaderapp.com So it appears that actually getting the vaccine is pretty much useless because this virus over the course of a few months will mutate and render the body's antibody response 'hors de combat". But the "good news", IMO is that I've relied upon the EARLY treatment and prophylactic treatment angle, namely Zinc + Zinc Ionophores (HCQ.. Quercetin, EGCG.. etc) and now Ivermectin, which is showing amazing effectiveness. THESE protocols have little to do with preventing the Virus from binding to the cells (antibody defense) and everything to do with preventing the invading Virus from being able to replicate within any cell it might manage to invade. But what do you think the consequences for market psychology, as well as economic recovery will be as this news gets out and about (and it will).. I can't tell anyone what to do, but it increases my determination to avoid exposure to these vaccines. I'll stick with what I've very certain IS WORKING. Hawk

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next